Table 1 Patient and tumor characteristics by Prosigna (PAM50) subtype.

From: The Prosigna 50-gene profile and responsiveness to adjuvant anthracycline-based chemotherapy in high-risk breast cancer patients

Characteristics	Trial population		Study population		Molecular subtype
	Trial population		Study population		Luminal A		Luminal B		Basal-like		Her2-E		P^a
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
No. of patients	962		686		132	19	78	11	259	38	217	32
Age													<0.0001
<40 years	163	17	97	14	17	13	13	17	46	18	21	10
40–49 years	472	49	345	50	87	66	48	62	120	46	90	41
50–59 years	201	21	155	23	15	11	10	13	69	27	61	28
60–69 years	126	13	89	13	13	10	7	9	24	9	45	21
Menopausal status													<0.0001
Pre	688	72	475	69	116	88	68	87	177	68	114	53
Post	274	28	211	31	16	12	10	13	82	32	103	47
Loco-regional therapy													0.02
BCS	187	19	114	17	27	20	17	22	50	19	20	9
M −RTG	576	60	416	61	80	61	44	56	154	59	138	64
M +RTG	197	20	154	22	25	19	17	22	53	20	59	27
M ?RTG	2	0.2	2	0.3	0	0	0	0	2	1	0	0
Lymph node status													<0.0001
Negative	352	37	244	36	70	53	42	54	99	38	33	15
1–3 positive	321	33	222	32	33	25	21	27	90	35	78	36
4+ positive	289	30	220	32	29	22	15	19	70	27	106	49
Tumor size													0.0002
0–20 mm	422	44	272	40	75	57	32	41	94	36	71	33
21–50 mm	462	48	357	52	52	39	41	53	145	56	119	39
>50 mm	73	8	57	8	5	4	5	6	20	8	27	4
Unknown	5	1	0	0	0	0	0	0	0	0	0	0
Histologic type													0.004
Ductal	897	93	642	94	123	93	77	99	236	91	206	95
Lobular	19	2	12	2	6	5	1	1	2	1	3	1
Other	42	4	31	5	3	2	0	0	20	8	8	4
Unknown	4	0.4	1	0.1	0	0	0	0	1	0.4	0	0
Malignancy grade^b													<0.0001
Grade I	67	7	35	5	17	14	4	5	5	2	9	4
Grade II	474	53	335	52	89	72	59	77	73	31	114	55
Grade III	356	40	272	42	17	14	14	18	158	67	83	40
ER status													<0.0001
Positive	202	21	155	23	68	52	47	60	6	2	34	16
Negative	420	44	328	48	19	14	8	10	183	71	118	54
Unknown	340	35	203	30	45	34	23	29	70	27	65	30
HER2													<0.0001
Normal	586	61	463	67	116	88	69	88	246	95	32	15
Positive	288	30	223	33	16	12	9	12	13	5	185	85
Unknown	88	9	0	0	0	0	0	0	0	0	0	0
TOP2A													<0.0001
Deletion	87	9	67	10	8	6	3	4	12	5	44	20
Normal	594	62	451	66	99	75	62	79	208	80	82	38
Amplification	92	10	77	11	6	5	4	5	11	4	56	26
Unknown	189	20	91	13	19	14	9	12	28	11	35	16
Chemotherapy													0.18
CMF	515	54	362	53	59	45	44	56	145	56	114	53
CEF	447	46	324	47	73	55	34	44	114	44	103	47

Her2-E Her2-enriched, BCS breast conserving surgery, M mastectomy, RT radiotherapy, CMF cyclophosphamide, methotrexate and fluorouracil, CEF cyclophosphamide, epirubicin and fluorouracil.
^aTest of categorical variable versus molecular subtype.
^bDuctal carcinomas only.

Back to article page

Table 1 Patient and tumor characteristics by Prosigna (PAM50) subtype.

Search

Quick links